AKAntje Knöll

Antje Knöll

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Antje Knöll has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Wolfgang Jilg

    Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany

    4 shared publications
  • Anette Rohrhofer

    Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany

    1 shared publication
  • Arndt Hartmann

    1 shared publication
  • Bernd Kochanowski

    Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany

    1 shared publication
  • E Holler

    Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany

    1 shared publication
  • E. Holler

    Department of Haematology/Oncology, University of Regensburg, Regensburg, Germany

    1 shared publication

Latest Publications

  • Long‐term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor

    by A. Knöll, S. Boehm, J. Hahn, E. Holler, W. Jilg

    Summary.  Reactivation of resolved hepatitis B virus (HBV) infection is increasingly recognized in patients with severe immunosuppression. We monitored seven patients with pretransplant antibodies to hepatitis B surface antigen (anti‐HBs) and hepatitis B core antigen (anti‐HBc) for HBV reactivation after allogeneic haematopoietic stem cell transplantation (allo‐HSCT). Reverse seroconversion (from anti‐HBs to HBsAg) was observed in six recipients occurring 12, 14, 16, 22, 31 and 39 months after allo‐HSCT, respectively. The only patient without HBV reactivation had the highest pretransplant anti‐HBs titre and died after the shortest follow‐up period (25 months). A novel HBV surface mutant (D144G/G145E) was isolated from one recipient of stem cells from a donor vaccinated against HBV. Another surface mutant (P142L/G145R) was detected in a recipient from a non‐immune donor. Serum ALT elevation was measured in only two of the six patients with viral reactivation, followed by spontaneous clearance of HBsAg in one of them. Antiviral treatment reduced viral load in five patients, but the emergence of YMDD motif polymerase mutations resulted in lamivudine resistance in two patients. In conclusion, the risk of reactivation of a resolved HBV infection is close to 100% in allogeneic stem cell recipients and vaccination of the donor does not always warrant reliable protection.


  • Serological pattern “anti-HBc alone”: Characterization of 552 individuals and clinical significance

    by Antje Knöll

    AIM: To investigate the prevalence and clinical significance of “anti-HBc alone” in an unselected population of patients and employees of a university hospital in southern Germany.


  • Solid-Organ Transplantation in HBsAg-Negative Patients with Antibodies to HBV Core Antigen: Low Risk of HBV Reactivation

    by Antje Knöll, Miriam Pietrzyk, Martin Loss, Wolfgang A. Goetz, Wolfgang Jilg

    Hepatitis B virus (HBV) reactivation is a well-described event in HBV surface antigen (HbsAg)-positive patients undergoing immunosuppression. There are only few data about the risk of HBV reactivation in HBsAg-negative solid-organ transplant recipients with resolved HBV infection. We conducted a systematic screening of serum and liver samples from 38 HBsAg-negative and anti-HBV core antigen (anti-HBc)-positive patients for the presence of HBV-DNA and for serologic HBV markers before and after solid-organ transplantation (kidney, n=23; liver, n=9; heart, n=6). Pretransplant prevalence of HBV-DNA was 24% (6/25) in serum and 33% (3/9) in liver samples. Forty-four percent (15/34) of the recipients were viremic after transplantation; this finding was more common in patients coinfected with hepatitis C (P=0.011) and in patients negative for anti-HBs (P=0.001). Two recipients became antigenemic (HBsAg-positive), but none developed clinical signs of hepatitis. In conclusion, subclinical reactivation of HBV infection was detected in a significant proportion of HBsAg-negative solid–organ-transplant recipients.


  • Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation

    by A Knöll, S Boehm, J Hahn, E Holler, W Jilg

    Hepatitis B virus (HBV) reactivation after allogeneic haematopoietic stem cell transplantation (allo-HSCT) is well known in HBsAg-positive carriers but has only occasionally been reported in patients with resolved HBV infection. We investigated six allo-HSCT recipients with pretransplant anti-HBs and anti-HBc antibodies for serologic markers of HBV infection and for the presence of HBV-DNA in serum. Reverse seroconversion, that is, reappearance of HBsAg after a gradual loss of anti-HBs, but no severe liver damage was observed in three patients at 14, 22 and 12 months after HSCT, respectively. There was an increase in HBV-DNA concentration prior to reverse seroconversion. One patient was repeatedly HBV-DNA positive (102–103 copies/ml) without reverse seroconversion. Sequencing of the HBsAg and precore region derived from the four HBV-DNA-positive patients showed no relevant mutations. In conclusion, this study demonstrated a high risk (50%) of reverse seroconversion in allo-HSCT recipients with resolved HBV infection. A highly sensitive HBV-DNA assay (TaqMan-PCR) allowed early identification of the individual patients at risk.


  • Low frequency of human polyomavirus BKV and JCV DNA in urothelial carcinomas of the renal pelvis and renal cell carcinomas

    by Antje Knöll, Robert Stoehr, Wolfgang Jilg, Arndt Hartmann

    Human polyomaviruses BKV and JCV establish a persistent infection in the kidney and possess oncogenic potential in experimental animal models. Their possible involvement in the pathogenesis of human urogenital tumors has been suggested by several studies but is not conclusively resolved. For the present study, highly sensitive quantitative TaqMan PCR assays were developed to detect BKV and JCV DNA sequences in matched pairs of human tumors and surrounding normal tissue. Samples from 55 patients with renal pelvic urothelial carcinomas and from 83 patients with renal cell carcinomas of all histologic subtypes were investigated. Human polyomavirus DNA was detected in renal pelvis samples with a frequency of 16% (BKV) and 15% (JCV), and in kidney samples with a frequency of 1% (BKV) and 23% (JCV), respectively. However, viral sequences were not present more often in tumors than in normal tissue. There was no integration of the potentially oncogenic viral large T-antigen in the tumors, and the viral concentration of both BKV and JCV was not higher in DNA extracted from tumors compared to normal tissue. These data provide no evidence for a causative role of the human polyomaviruses BKV and JCV in the development of tumors of the renal pelvis and the kidney.


  • Prevalence of precore mutants in anti‐HBe‐positive hepatitis B virus carriers in Germany

    by Antje Knöll, Anette Rohrhofer, Bernd Kochanowski, Eva‐Maria Wurm, Wolfgang Jilg

    Hepatitis B virus (HBV) precore mutants are associated often with highly productive infection in hepatitis B surface antigen (HBsAg) carriers lacking hepatitis B e antigen (HBeAg) but positive for anti-HBe, rendering serological identification of infectious individuals unreliable. Although considered initially to be limited mostly to the Mediterranean area, more recent studies suggest a significant presence of these mutants in northern European countries. The sequence of the precore region was determined and examined for mutations from HBV isolates of 99 German chronic HBsAg carriers positive for HBV-DNA and either HBeAg (n = 15) or anti-HBe (n = 84). In addition, clinical data of individuals carrying wild-type virus and those with precore mutants were compared. HBV precore mutants were found in more than half (44/84) of all HBeAg-negative, anti-HBe-positive virus carriers. There was no difference between carriers of wild-type and precore mutant HBV in the level of viremia or in the clinical course of chronic infection. In conclusion, HBV precore mutants are common in Germany and can therefore present a diagnostic problem for serological testing. However, precore mutants do not appear to have a detrimental effect on the course of chronic HBV infection. J. Med. Virol. 59:14–18, 1999.